Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487064 | 0.78 | ALDH1A1 (0.54) | ALDH1A1TSHRLMNAL3MBTL1KDM4E | |
| SCHEMBL8979322 | 0.77 | ACHE (0.46) | ALDH1A1CYP3A4LMNANPC1MAPT | |
| SCHEMBL8979210 | 0.75 | HTR3E (0.50) | TSHRLMNAL3MBTL1NPC1TP53 | |
| SCHEMBL8979321 | 0.75 | ACHE (0.41) | ALDH1A1CYP3A4KDM4ENPC1MAPT | |
| SCHEMBL28021366 | 0.75 | ALDH1A1 (0.63) | ALDH1A1CYP3A4TSHRLMNAKDM4E | |
| SCHEMBL11638767 | 0.74 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TSHRL3MBTL1KDM4E | |
| SCHEMBL677668 | 0.72 | LMNA (0.46) | ALDH1A1TSHRLMNAL3MBTL1MAPT | |
| SCHEMBL8979323 | 0.72 | MTNR1A (0.48) | ALDH1A1CYP3A4 | |
| SCHEMBL8979327 | 0.72 | GAA (0.41) | ALDH1A1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4978628 | 0.71 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TSHRL3MBTL1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188097-B2 | Pyrazolo[1,5-A]pyrimidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| WO-2012058203-A1 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | ALDH1A1 467/4885CYP3A4 456/4885TSHR 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.